AZALEA
Trial Details
- Trial statusClosed
- Study email contactazaleatrial@imperial.ac.uk
- Chief InvestigatorProfessor Sebastian Johnston
- Project managern/a - study complete
- SponsorImperial College, London
- Phase4
A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients with Acute Exacerbations of Asthma
Design and Objective
This is a randomised, double-blind, placebo-controlled study to evaluate the efficacy of Azithromycin in addition to standard care for adult patients who have an acute exacerbation of asthma / asthma attack. The main objective is to determine if Azithromycin has a significant effect on reduction in patient reported symptoms compared to placebo. We will also study mechanisms for why it may be effective.
Key inclusion criteria
Adults 18 and over of either sex with a documented history of asthma for >6 consecutive months, with a PEF or FEV1 less than 80% of predicted normal and presenting with 48 hours (of initial presentation to medical care) with an acute deterioration in asthma control and requiring a course of oral steroids.